Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
63020-0078-01 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov 20, 2015 No Longer Used
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
75007-0501-32 75007-0501 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Dec 17, 2025 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
55150-0337-02 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
63020-0078-02 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov 20, 2015 Oct 31, 2023 No Longer Used
63020-0049-01 63020-0049 Bortezomib Velcade 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 13, 2003 In Use
72205-0183-01 72205-0183 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 27, 2022 In Use
83090-0008-01 83090-0008 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 15, 2023 In Use
31722-0303-31 31722-0303 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 3, 2024 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
70069-0836-01 70069-0836 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Apr 29, 2025 In Use
50742-0484-01 50742-0484 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 Apr 30, 2026 In Use
70511-0162-02 70511-0162 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug 11, 2022 In Use
76075-0103-01 76075-0103 carfilzomib KYPROLIS 10.0 mg/5mL Chemotherapy Proteasome Inhibitor 20S Intravenous May 23, 2018 In Use
68083-0650-01 68083-0650 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jan 6, 2026 In Use
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 27, 2022 In Use
00409-1700-01 00409-1700 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 27, 2022 In Use
68001-0541-36 68001-0541 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 31, 2022 In Use
59762-0850-07 59762-0850 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct 30, 2007 Feb 29, 2016 No Longer Used
70786-0090-01 70786-0090 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Aug 3, 2016 Aug 5, 2016 No Longer Used
00006-4121-01 00006-4121 Human Papillomavirus 9-valent Vaccine, Recombinant GARDASIL 9 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular Dec 10, 2014 In Use
50436-0446-03 50436-0446 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Aug 18, 2011 Dec 31, 2017 In Use
31722-0525-01 31722-0525 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Aug 1, 2010 In Use

Found 12250 results — Export these results